Search
This methodology has significant potential to identify covert interactions between inflammatory pathways triggered by vaccination, and as such may be a...
Vaccines including conserved antigens from Streptococcus pneumoniae & nontypeable Haemophilus influenzae have the potential to reduce of otitis media.
We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PApilloma TRIal against Cancer In young Adults.
We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young...
The authors previously reported an increased risk of hospitalisation for acute lower respiratory infection up to age 2 years in children delivered by...
In 2017, a steep rise in cases of meningococcal disease caused by the W strain sparked a wave of concern for parents in Western Australia.
New mothers in Perth are teaming up with researchers at The Kids Research Institute Australia in a global bid to develop the first vaccine to prevent Respiratory Syncytial Virus (RSV) disease.
Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Honorary and NHMRC Career Development Fellow, Paediatric Infectious Diseases Physician and Clinical Microbiologist
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Acute lower respiratory tract infection (ALRI) remains a major worldwide cause of childhood mortality, compelling innovation in prevention and treatment. Children in Papua New Guinea (PNG) experience profound morbidity from ALRI caused by Streptococcus pneumoniae. As a result of evolutionary divergence, the human PNG population exhibits profound genetic variation and diversity. To address unmet health needs of children in PNG, we tested whether genetic variants increased ALRI morbidity.